Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Abstract Background Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF V600-mutated melanoma treated in the Phase III coBRIM study. Methods In the coBRIM stud...

Full description

Bibliographic Details
Main Authors: Luis de la Cruz-Merino, Lorenza Di Guardo, Jean-Jacques Grob, Alfredo Venosa, James Larkin, Grant A. McArthur, Antoni Ribas, Paolo A. Ascierto, Jeffrey T. R. Evans, Antonio Gomez-Escobar, Giulio Barteselli, Susan Eng, Jessie J. Hsu, Anne Uyei, Brigitte Dréno
Format: Article
Language:English
Published: BMC 2017-06-01
Series:Journal of Translational Medicine
Subjects:
Cobimetinib
MEK inhibition
Melanoma
Serous retinopathy
Visual disturbance
Online Access:http://link.springer.com/article/10.1186/s12967-017-1246-0

Internet

http://link.springer.com/article/10.1186/s12967-017-1246-0

Similar Items